Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pain relief for tiny hearts: study tests EXPAREL in kids under 6

NCT ID NCT06271265

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for children under 6 years old who need heart surgery. It tests a pain medicine called EXPAREL to see if it works well and is safe compared to a standard painkiller. The medicine is given near the surgery area to help with pain after the operation. About 48 children will take part.

Why investors are watching

Pacira is testing EXPAREL, its long-acting painkiller, in children under 6 having heart surgery. This is a small, early-stage study with only 48 participants, but it matters because EXPAREL is the company's main product, and showing it works safely in a new, younger patient group could broaden its use. For a small company that depends on one drug, any readout on that drug's reach is consequential.

If it works: A positive result could support expanding EXPAREL's label to include young children, opening a new market for the company's core product. It could also reassure investors that the drug has a future beyond its current adult uses.

If it fails: The trial could fail to show adequate pain relief or safety in children, which would block that expansion. Early-phase trials in small groups often fail, and a setback here would leave Pacira with fewer growth options for its main drug.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

0 to 6 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All of the following inclusion criteria must be met for eligibility: 1. Pediatric participants with congenital heart defects planned to undergo cardiac surgery with cardiopulmonary bypass 2. Male or female participants from 0 to less than 6 years of age on the day of surgery: 2 years to less than 6 years of age for Part 1; 6 months to less than 2 years of age for Part 2; 0 to less than 6 months of age for Part 3 3. American Society of Anesthesiologists (ASA) Classes 1 through 4. 4. Parent/guardian is able to speak, read, and understand the language of the ICF and provide informed consent for the participant. 5. Parent/guardian is able to adhere to the study visit schedule and complete all study assessments for the participant. Exclusion Criteria: Exclusion Criteria: A participant will not be eligible for the study if any of the following exclusion criteria are met: 1. History of hypersensitivity or idiosyncratic reactions or contradictions to EXPAREL, bupivacaine HCl, or other amide-type local anesthetics or to opioid medications 2. Administration of EXPAREL or bupivacaine HCl within 30 days prior to IP administration 3. Administration of an IP within 30 days or 5 elimination half-lives of such IP, whichever is longer, prior to IP administration, or planned administration of another IP or procedure during participation in this study 4. History of preterm birth (before 35 weeks of pregnancy) 5. History of coagulopathies or immunodeficiency disorders 6. Disease or condition that, in the opinion of the Investigator, indicates an increased vulnerability to IPs and/or procedures 7. Recent or potential exposure to COVID-19 8. Cardiac surgery has been canceled and cannot be rescheduled within 30 days of signing the ICF because of any reason. 9. Necessity in delayed wound closure 10. Informed consent withdrawn before randomization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Congenital heart defects are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Duke University Health System

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Indiana University Health, Riley Hospital For Children

    RECRUITING

    Indianapolis, Indiana, 46202, United States

  • St. Louis Children's Hospital (SLCH)

    RECRUITING

    St Louis, Missouri, 63110, United States

  • The University of Texas Health Science Center at Houston (UTHSC-H) - McGovern Medical School

    RECRUITING

    Houston, Texas, 77030, United States

  • University of Oklahoma (OU) - Medical Center - The Children's Hospital

    RECRUITING

    Oklahoma City, Oklahoma, 73104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.